Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Inclisiran · Leqvio

Other · Gene silencing: proprotein convertase subtilisin/kexin type 9 (PCSK9) · developed by Novartis

Approved FDA, Dec 2021
NVS Developer
3 Registered trials

What is Inclisiran?

Inclisiran is a double-stranded small interfering RNA conjugated to GalNAc to target hepatocytes, where it directs the breakdown of PCSK9 mRNA. This reduces PCSK9 protein production, increasing LDL-C receptor recycling and LDL-C clearance from the circulation. It is studied in atherosclerotic cardiovascular disease, primary prevention and cardiometabolic syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Leqvio
Drug type
Other
Targets
proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism
Gene silencing: proprotein convertase subtilisin/kexin type 9 (PCSK9)
Pathways
LDL-C receptor recycling, hepatic LDL-C uptake
Therapy area
Cardiovascular, Metabolic
Developer
Novartis (NVS)
FDA status
Approved as Leqvio (December 22, 2021), NDA214012 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 19, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06909565 Phase 4 Percutaneous Coronary Intervention Recruiting NVS
NCT07102628 Phase 3 Acute Coronary Syndrome Active not recruiting NVS
NCT05030428 Phase 3 Atherosclerotic Cardiovascular Disease Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atherosclerotic Cardiovascular DiseaseCardiometabolic SyndromeDrug InteractionsLDL-Cholersterol LoweringPolypharmacyPrimary Prevention

Other drugs acting on PCSK9

More from Novartis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Inclisiran

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.